383 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Allergan PLC (AGN) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/05/07/allergan-plc-agn-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 May 07, 2019 - AGN earnings call for the period ending May 7, 2019.
Why Are Investors Passing on Teva Pharmaceutical Industries? https://www.fool.com/investing/2019/05/05/why-are-investors-passing-on-teva-pharmaceutical-i.aspx?source=iedfolrf0000001 May 05, 2019 - Teva's turnaround won't kick into high gear anytime soon.
Why the Earnings Surprise Streak Could Continue for Allergan (AGN) http://www.zacks.com/stock/news/408551/why-the-earnings-surprise-streak-could-continue-for-allergan-agn?cid=CS-ZC-FT-408551 May 03, 2019 - Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down http://www.zacks.com/stock/news/408333/teva-teva-q1-earnings-beat-copaxone-drags-sales-down?cid=CS-ZC-FT-408333 May 03, 2019 - Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Can Allergan (AGN) Beat Earnings Estimates Again in Q1? http://www.zacks.com/stock/news/406700/can-allergan-agn-beat-earnings-estimates-again-in-q1?cid=CS-ZC-FT-406700 May 01, 2019 - Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release http://www.zacks.com/stock/news/405780/allergan-agn-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release?cid=CS-ZC-FT-405780 Apr 30, 2019 - Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards? http://www.zacks.com/stock/news/405122/teva-teva-to-report-q1-earnings-whats-in-the-cards?cid=CS-ZC-FT-405122 Apr 29, 2019 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.
Is a Beat in Store for Editas (EDIT) This Earnings Season? http://www.zacks.com/stock/news/402783/is-a-beat-in-store-for-editas-edit-this-earnings-season?cid=CS-ZC-FT-402783 Apr 25, 2019 - On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? http://www.zacks.com/stock/news/398971/pfizer-pfe-to-report-q1-earnings-will-it-beat-estimates?cid=CS-ZC-FT-398971 Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Alkermes Reports Positive Data From Schizophrenia Study http://www.zacks.com/stock/news/377786/alkermes-reports-positive-data-from-schizophrenia-study?cid=CS-ZC-FT-377786 Apr 10, 2019 - Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

Pages: 1234567891011...39

<<<Page 6>